TTPH Tetraphase Pharmaceuticals, Inc

8.18
+0  (1%)
Previous Close 8.10
Open 8.20
Price To book 2.14
Market Cap 303.13M
Shares 37,057,000
Volume 480,121
Short Ratio 2.39
Av. Daily Volume 619,016

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial did not meet endpoints September 2015. Additional Phase 3 trial initiation announced January 17, 2016.
Eravacycline (TP-434) - IGNITE3
cUTI - complicated urinary tract infections
Announced Dec 17, 2014 that their Phase 3 trial met endpoints. Noted April 3, 2017 that enrollment has completed in its additional Phase 3 trial (IGNITE-4) with data due 3Q 2017.
Eravacycline (TP-434) - IGNITE4
cIAI (complicated intra-abdominal infections)

Latest News

  1. Implied Volatility Surging for Tetraphase Pharmaceuticals (TTPH) Stock Options
  2. Tetraphase Pharmaceuticals to Present Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  3. Tetraphase Pharmaceuticals Completes Enrollment of IGNITE4 Phase 3 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections
  4. ​These 5 Mass. biotechs are getting $12M to fight ‘superbugs’
  5. Tetraphase Pharmaceuticals’ TP-6076 Selected by CARB-X to Receive $4 Million in Research Funding
  6. ETFs with exposure to Tetraphase Pharmaceuticals, Inc. : March 27, 2017
  7. Tetraphase Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
  8. Tetraphase Pharmaceuticals, Inc. :TTPH-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  9. 5 Biotech Stocks That Could Skyrocket From Upcoming Catalysts
  10. Are Options Traders Betting on a Big Move in Tetraphase (TTPH) Stock?
  11. Tetraphase Pharmaceuticals, Inc. :TTPH-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
  12. Today's Research Reports on Biotech Stocks to Watch: Inotek Pharmaceuticals and Tetraphase Pharmaceuticals
  13. Tetraphase Pharmaceuticals Inc Is Climbing Again Today -- Here's Why
  14. Tetraphase reports 4Q loss
  15. Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Highlights Key 2017 Milestones
  16. Tetraphase Pharmaceuticals to Present at the 29th Annual ROTH Conference
  17. Tetraphase Pharmaceuticals to Host Conference Call on March 8 to Discuss Fourth Quarter and Full Year 2016 Financial Results and Provide Corporate Update
  18. Tetraphase Says Antibiotic Has Strong Sales Prospects
  19. Tetraphase antibiotic may reach up to $700 mln in annual sales: CEO